CN113166134B - 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 - Google Patents
作为甲酰肽2受体激动剂的吡咯烷酮衍生物 Download PDFInfo
- Publication number
- CN113166134B CN113166134B CN201980077329.9A CN201980077329A CN113166134B CN 113166134 B CN113166134 B CN 113166134B CN 201980077329 A CN201980077329 A CN 201980077329A CN 113166134 B CN113166134 B CN 113166134B
- Authority
- CN
- China
- Prior art keywords
- methoxyphenyl
- difluoro
- amino
- pyrrolidin
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771196P | 2018-11-26 | 2018-11-26 | |
| US62/771,196 | 2018-11-26 | ||
| US201962819832P | 2019-03-18 | 2019-03-18 | |
| US62/819,832 | 2019-03-18 | ||
| PCT/US2019/062905 WO2020112583A1 (en) | 2018-11-26 | 2019-11-25 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113166134A CN113166134A (zh) | 2021-07-23 |
| CN113166134B true CN113166134B (zh) | 2024-06-14 |
Family
ID=68848531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980077329.9A Active CN113166134B (zh) | 2018-11-26 | 2019-11-25 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12281108B2 (OSRAM) |
| EP (1) | EP3887366B1 (OSRAM) |
| JP (1) | JP7398455B2 (OSRAM) |
| KR (1) | KR102877973B1 (OSRAM) |
| CN (1) | CN113166134B (OSRAM) |
| ES (1) | ES2964299T3 (OSRAM) |
| WO (1) | WO2020112583A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038515A (ko) * | 2020-07-09 | 2023-03-20 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 fpr2 효능제 |
| JP7700210B2 (ja) | 2020-07-09 | 2025-06-30 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| JP7802765B2 (ja) * | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| JP7830488B2 (ja) * | 2021-01-21 | 2026-03-16 | ベイジン・ティアンタン・ホスピタル | Ｆｐｒ１のモジュレーター及びそれを使用する方法 |
| WO2022155860A1 (en) * | 2021-01-21 | 2022-07-28 | Biofront Therapeutics (Beijing) Co., Ltd. | Modulators of fpr1 and methods of using the same |
| WO2022193187A1 (en) * | 2021-03-17 | 2022-09-22 | Biofront Ltd. (Cayman) | Modulators of fpr1 and methods of using same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ752095A (en) | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| US10525058B2 (en) | 2015-05-27 | 2020-01-07 | Kyorin Pharmaceutical Co., Ltd | Urea derivative or pharmacologically acceptable salt thereof |
| US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| JP2018538367A (ja) | 2015-11-24 | 2018-12-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 |
| KR102772801B1 (ko) | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| TW201815762A (zh) * | 2016-09-21 | 2018-05-01 | 德商歌林達有限公司 | 經尿素及苯基取代之６員環狀胺或內醯胺 |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| US11767291B2 (en) * | 2017-05-17 | 2023-09-26 | William Marsh Rice University | Preparation of secondary amines with electrophilic N-linchpin reagents |
| CN110996950B (zh) | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂 |
| ES2869129T3 (es) | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| EP3634958B1 (en) | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| SG11202008504SA (en) | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2946673T3 (es) | 2019-06-18 | 2023-07-24 | Bristol Myers Squibb Co | Agonistas del FPR2 de óxido de biaril dialquil fosfina |
-
2019
- 2019-11-25 ES ES19818484T patent/ES2964299T3/es active Active
- 2019-11-25 KR KR1020217019403A patent/KR102877973B1/ko active Active
- 2019-11-25 JP JP2021529452A patent/JP7398455B2/ja active Active
- 2019-11-25 WO PCT/US2019/062905 patent/WO2020112583A1/en not_active Ceased
- 2019-11-25 US US17/295,092 patent/US12281108B2/en active Active
- 2019-11-25 CN CN201980077329.9A patent/CN113166134B/zh active Active
- 2019-11-25 EP EP19818484.8A patent/EP3887366B1/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists;Nicholas R. Wurtz et al.;《ACS Medicinal Chemistry Letters》;第13卷;943-948 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12281108B2 (en) | 2025-04-22 |
| CN113166134A (zh) | 2021-07-23 |
| EP3887366B1 (en) | 2023-09-27 |
| US20220002281A1 (en) | 2022-01-06 |
| ES2964299T3 (es) | 2024-04-05 |
| JP7398455B2 (ja) | 2023-12-14 |
| KR20210095897A (ko) | 2021-08-03 |
| WO2020112583A1 (en) | 2020-06-04 |
| JP2022508218A (ja) | 2022-01-19 |
| EP3887366A1 (en) | 2021-10-06 |
| KR102877973B1 (ko) | 2025-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3887366B1 (en) | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists | |
| US11530183B2 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| US20210371378A1 (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| KR102623473B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| EP3986903A1 (en) | Biaryl dialkyl phosphine oxide fpr2 agonists | |
| CN116034104B (zh) | 氧代吡咯烷fpr2激动剂 | |
| CN116057055B (zh) | 氧代吡咯烷脲类fpr2激动剂 | |
| ES2986512T3 (es) | Agonistas del receptor 2 del péptido formil pirazolona | |
| CN116390913A (zh) | 氨基咪唑fpr2激动剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |